At Prisma Health Stroke Center, we are constantly researching new ways to treat and prevent stroke. Our carefully controlled inpatient and outpatient clinical trials follow specific protocols to test safety and/or effectiveness treatments, medications and devices.
For clinical trials to be successful, willing participants are needed. Participants help further medical knowledge and other patients – call 803-545-6050 for more information. View our Current Clinical Trials
Prisma Health Stroke Center researchers are having an impact on national guidelines for treating stroke patients.
Selected as the only Southeastern site of 38 participating research centers in the National Institutes of Health-funded DEFUSE 3 clinical trial, Prisma Health was part of a team of investigators that set a new guideline increasing the window of time for blood clots to be mechanically removed from vessels supplying the brain. Learn more »
View the trial results in the New England Journal of Medicine »
A phase 2, safety and efficacy study of ALZT-OP1A AS adjuvant treatment in subjects with post-ischemic stroke cognitive impairment (PSCI)
A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Response-Adaptive Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA).
Developing a regional integrated stroke system of care to improve the speed of cerebral reperfusion therapy. Establish best clinical practices and data management.
This phase 3 clinical trial is looking at the effectiveness of MultiStem for the treatment of ischemic stroke as compared to placebo. MultiStem cell therapy for the treatment of ischemic stroke has the potential to target multiple reparative and anti-inflammatory processes after stroke onset.
Prediction of Outcome of Language Rehabilitation - Project 1 of the Center for the Study of Aphasia Recovery (C-STAR)
To investigate a variety of factors (e.g., biographical, cognitive/linguistic, and patterns of brain damage) that predict an individual's response to aphasia treatment (semantic & phonological).
PeRiodontal treatment to Eliminate Minority InEquality and Rural disparities in Stroke (PREMIERS) is a phase III randomized controlled trial to assess the hypothesis that periodontal treatment reduces the risk of recurrent vascular events in ischemic stroke and TIA survivors.
Funded by: National Institutes for Neurological Disease and Stroke (NINDS)
YSQ: Prospective Young Stroke Questionnaire Validation
YSQ is a one-year single-center pilot research project to build upon the knowledge and understanding of young stroke and the specificities of treatment, management, and long-term outcome that are relevant to young stroke survivors.
The primary goal of this Phase III study is to determine whether treatment of OSA with positive airway pressure starting shortly after stroke or mini-stroke reduces recurrent stroke, acute coronary syndrome, and all-cause mortality. Eligible subjects are ≥18 years of age, which have experienced a qualifying TIA or ischemic stroke within the prior 14 days.
Young ESUS is a longitudinal prospective observational patient registry to build upon the knowledge and understanding of Young ESUS and the long-term outcomes.
DESIRE is a single-center cohort design for a prospective ICH registry, with the intention to evaluate the effect of pathophysiologically-guided and evidence based care on patient outcomes in the population of patients with ICH in South Carolina.
ARCADIA is a phase III study for patients with unexplained stroke and one of three biomarkers indicative of “atrial cardiopathy” in the absence of atrial fibrillation. These biomarkers, which indicate abnormalities of left atrial function or structure, include an elevation of NT-proBNP, increased P wave terminal force velocity, or enlargement of the left atrium on cardiac echo. Patients enrolled in the study who have one of these abnormalities will be assigned to take either apixaban (Eliquis) or aspirin 81 mg daily.
To conduct an implementation trial (at the patient level) of the PACESETTER intervention [health technology (personalized phone text messaging and home BP monitoring)] vs. usual care, in 200 recent stroke patients with HTN recruited across the three main safety net hospitals in the state of SC. Primary outcome is achievement of guideline-recommended systolic BP control at 12 months.
This is a Phase 2 multicenter, randomized, double-blind, placebo-controlled, add-on study of NBP softgel capsules for the treatment of adults who have experienced a mild to moderate AIS. The first dose must be taken within 12 hours of the onset of the AIS.
The aim of this initial pilot study is to obtain preliminary data on HRMRI imaging features (wall thickening, enhancement, stenosis, plaque characteristics) of large intracranial arteries (middle cerebral, intracranial carotid, basilar, vertebral) that have undergone mechanical thrombectomy and describe the changes related to different thrombectomy devices.
March 25, 2020